Eyevance Pharmaceuticals has acquired Tobradex ST and Natacyn from Novartis, according to a press release.
Tobradex ST (tobramycin 0.3%/dexamethasone 0.05% ophthalmic suspension), a fixed-dose topical antibiotic and corticosteroid combination for steroid-responsive inflammatory ocular conditions, and Natacyn (natamycin ophthalmic suspension 5%), an ocular antifungal, are Eyevance’s latest milestones in its growth strategy, the release said.
“The acquisition of Tobradex ST and Natacyn further demonstrates Eyevance’s commitment and mission to serve the doctors that treat patients’
Uncategorized